alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

  <ARTICLE>                              5
  <CIK>                                  0001013148
  <NAME>                                 Xybernaut Corporation
         
  <S>                  <C>          
  <FISCAL-YEAR-END>        Dec-31-1998
 <PERIOD-START>            Jul-01-1998
  <PERIOD-END>             Sep-30-1998
  <PERIOD-TYPE>            3-MOS
  <CASH>                                 814,266
  <SECURITIES>                              0
  <RECEIVABLES>                          279,242
  <ALLOWANCES>                            22,513
  <INVENTORY>                            741,469
  <CURRENT-ASSETS>                      2,509,616
  <PP&E>                                 982,329
  <DEPRECIATION>                         537,847
  <TOTAL-ASSETS>                        3,827,497
  <CURRENT-LIABILITIES>                 1,145,357
  <BONDS>                                   0
  <COMMON>                               202,085
  <PREFERRED-MANDATORY>                     0
  <PREFERRED>                            273,566
  <OTHER-SE>                            3,351,846
  <TOTAL-LIABILITY-AND-EQUITY>          3,827,497          
  <SALES>                                259,043
  <TOTAL-REVENUES>                       259,043
  <CGS>                                  794,793
  <TOTAL-COSTS>                          794,793
  <OTHER-EXPENSES>                      2,968,163
  <LOSS-PROVISION>                          0
  <INTEREST-EXPENSE>                        0
  <INCOME-PRETAX>                      (3,480,275)
  <INCOME-TAX>                              0
  <INCOME-CONTINUING>                  (3,480,275)
  <DISCONTINUED>                            0
  <EXTRAORDINARY>                           0
  <CHANGES>                                 0
  <NET-INCOME>                         (3,480,275)
  <EPS-PRIMARY>                           (.18)
  <EPS-DILUTED>                           (.18)
        

</TABLE>
[Federal Register Volume 89, Number 175 (Tuesday, September 10, 2024)]
[Notices]
[Page 73424]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-20370]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Advancing Translational Sciences; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Advancing Translational 
Sciences Special Emphasis Panel; NCATS CTSA UM1 Review Special 
Emphasis Panel.
    Date: October 30, 2024.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Center for Advancing Translational Sciences, 
National Institutes of Health, 9609 Medical Center Drive, Rockville, 
MD 20892 (Virtual).
    Contact Person: Victor Henriquez, Ph.D., Scientific Review 
Officer, Office of Scientific Review, National Center for Advancing 
Translational Sciences, National Institutes of Health, 9609 Medical 
Center Drive, Suite 1E504, Bethesda, MD 20892, (301) 435-0813, 
<a href="/cdn-cgi/l/email-protection#e9818c879b80989c9fa984888085c7878081c78e869f"><span class="__cf_email__" data-cfemail="b6ded3d8c4dfc7c3c0f6dbd7dfda98d8dfde98d1d9c0">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, 
Pharmacology, Physiology, and Biological Chemistry Research; 93.350, 
B--Cooperative Agreements; 93.859, Biomedical Research and Research 
Training, National Institutes of Health, HHS)

    Dated: September 4, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee 
Policy.
[FR Doc. 2024-20370 Filed 9-9-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Commerce Bureau of Industry and Security 15 CFR Part 744
 CFR Correction This rule is being published by the Office of the Federal Register to correct an editorial or technical error that appeared in the most recent annual revision of the Code of Federal Regulations. In Title 15 of the Code of Federal Regulations, Parts 300 to 799, revised as of January 1, 2024, in supplement number 4 to part 744, in the table, under NETHERLANDS, restore the entry for “Kapil Raj Arora”, and under PAKISTAN, restore the entry for “Orion Eleven Pvt. Ltd.”, to read as set forth below: Supplement No. 4 to Part 744—Entity List 
 
 
 Country
Entity
License 
                             requirement
License 
                             review policy
**Federal Register**
                             citation*         *         *         *         *         *         *NETHERLANDS
*         *         *         *         *         *Kapil Raj Arora, Breukelensestraat 44, 2574 RC, The Hague, Netherlands; 
                            *and*
                             Knobbelswaansingel 19, 2496 LN, The Hague, Netherlands
For all items subject to the EAR. (See § 744.11 of the EAR)
Presumption of denial
81 FR 14958, 3/21/16.*         *         *         *         *         *PAKISTAN
*         *         *         *         *         *Orion Eleven Pvt. Ltd., Street 11 Valley Road, Westridge Rawalpindi, Pakistan
For all items subject to the EAR. (See § 744.11 of the EAR)
Presumption of denial
79 FR 56003, 9/18/14.*         *         *         *         *         *


[FR Doc. 2024-21109 Filed 9-13-24; 8:45 am] BILLING CODE 0099-10-P
EXHIBIT 32.2
 SECTION 1350 CERTIFICATION *
 
  
 (1)
    
    The Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and(2)
    
    The information contained in the Report fairly presents, in all material respects, the
financial condition and result of operations of the Company.
 
 Dated October 12, 2010
    By:
    /s/ James A. McGradyJames A. McGrady, Chief Executive Officer,President, Chief Financial Officer and Treasurer
(Principal Executive Officer and Principal Financial
and Accounting Officer) 
 *
    
    This Certification is being furnished as required by Rule 13a-14(b) under the Securities
Exchange Act of 1934 (the Exchange Act) and Section 1350 of Chapter 63 of Title 18 of the
United States Code, and shall not be deemed filed for purposes of Section 18 of the
Exchange Act or otherwise subject to the liability of that section. This Certification shall
not be deemed to be incorporated by reference into any filing under the Securities Act of
1933 or the Exchange Act, except as otherwise stated in such filing.A signed original of this written statement required by 18 U.S.C. § 1350 has been provided to
the Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.
**Exhibit 31.1302 CERTIFICATION OF CHIEF EXECUTIVE OFFICEROF ALTERRA HEALTHCARE CORPORATION I, Patrick F. Kennedy, certify that:1.     I have reviewed this quarterly report on Form 10-Q of Alterra Healthcare Corporation;2.     Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; 3.     Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; 4.     The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:(a)      designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;(b)      evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and(c)     presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;5.     	The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):(a)     all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and(b)      any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and6.     	The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.Date:  November 14, 2003    /s/ Patrick F. Kennedy                              Patrick F. Kennedy,Chief Executive Officer**
II 

Calendar No. 353 

115TH CONGRESS 

2D SESSION S. 2527 

To amend the Small Business Investment Act of 1958 to increase the amount 

of leverage made available to small business investment companies. 

IN THE SENATE OF THE UNITED STATES 

MARCH 8, 2018 

Mr. CARDIN (for himself, Mr. RISCH, and Mr. KENNEDY) introduced the following bill; which was read twice and referred to the Committee on Small 

Business and Entrepreneurship 

MARCH 19, 2018 

Reported by Mr. RISCH, without amendment 

A BILL 

To amend the Small Business Investment Act of 1958 to 

increase the amount of leverage made available to small 

business investment companies. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Small Business Invest5 ment Opportunity Act of 2018’’. 


daltland on DSKBBV9HB2PROD with BILLS
2 

•S 2527 RS

1 SEC. 2. INDIVIDUAL SBIC LEVERAGE LIMIT INCREASE. 

2 Section 303(b)(2)(A)(ii) of the Small Business In3 vestment Act of 1958 (15 U.S.C. 683(b)(2)(A)(ii)) is 

4 amended by striking ‘‘$150,000,000’’ and inserting 

5 ‘‘$175,000,000’’. 


daltland on DSKBBV9HB2PROD with BILLS

daltland on DSKBBV9HB2PROD with BILLS
Calendar No. 353 

115TH CONGRESS 

2D SESSION S. 2527 

A BILL 

To amend the Small Business Investment Act of 

available to small business investment companies. 1958 to increase the amount of leverage made 

MARCH 19, 2018 

Reported without amendment 


daltland on DSKBBV9HB2PROD with BILLS
II 

115TH CONGRESS 

2D SESSION S. 2481 

To increase the penalties for fentanyl trafficking. 

IN THE SENATE OF THE UNITED STATES 

MARCH 1, 2018 

Mr. KENNEDY introduced the following bill; which was read twice and referred 

to the Committee on the Judiciary 

A BILL 

To increase the penalties for fentanyl trafficking. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Stop Trafficking in 

5 Fentanyl Act of 2018’’. 

6 SEC. 2. ENHANCED PENALTIES. 

7 Section 401(b)(1) of the Controlled Substances Act 

8 (21 U.S.C. 841(b)(1)) is amended— 

9 (1) in subparagraph (A)(vi)— 

10 (A) by striking ‘‘400 grams’’ and inserting 

11 ‘‘20 grams’’; and 


lotter on DSKBCFDHB2PROD with BILLS
2 

•S 2481 IS

1 (B) by striking ‘‘100 grams’’ and inserting 

2 ‘‘5 grams’’; and 

3 (2) in subparagraph (B)(vi)— 

4 (A) by striking ‘‘40 grams’’ and inserting 

5 ‘‘2 grams’’; and 

6 (B) by striking ‘‘10 grams’’ and inserting 

7 ‘‘0.5 grams’’. 

Æ 


lotter on DSKBCFDHB2PROD with BILLS
### IN THE UNI TED STATES COURT OFAPPEALS FOR THE FIF TH CIRCU IT

No. 10-20847 Conference Calendar
UNITED STATES OF AMERICA, Plaintiff-Appellee

v. DAN I E L REYNA-CASTANON, also known as Rudolfo Garza Gutierrez, also known as Roudolfo Garza Gutierrez, also known as Rodolfo Gu t i e rr e z , also known as Rodolpho Garza, also known as Rodolfo Garza Gutierrez, also known as Jesus Gutierrez, also known as Daniel Constantino R eyna Castanon, also known as Joe Perez, also known as Da n iel Constantine Reyna-Castonon, also known as Rudolfo Garza-Gutierrez, also known as Daniel Reyna Castanon, also known as Miguel Angel Reyna, Defendant-Appellant

Appeal from the United States District Court for the Southern District of Texas USDC No. 4:10-CR-344-1
Before DAVIS, STEWART, and PRADO, Circuit Judges. PER CURIAM: * The attorney appointed to r e p r esent Daniel Reyna-Castanon has moved f o r l e av e to withdraw and has filed a brief in accordance with Anders v . California , 386 U.S. 738 (1967), and United States v. Flores , 632 F.3d 229 (5th U n i te d S ta te s C o u rt o f A p p ea l s

F i ft h C i rc u i t 

### F I L E D June 19 , 20 12 Lyle W . Cayce Clerk

Purs uant to 5 T H C IR
. R. 47.5 , the cour t hasd ete rm inedt hat this op inion sho uld not * be publ ish ed and is not pr ece dent excep t unde r the lim ite d cir cum st ance s se t forth in 5 T H C IR
. R. 47.5 .4. Case: 10-20847 Document: 00511890978 Page: 1 Date Filed: 06/19/2012No. 10-20847

C ir. 2011). Reyna-Castanon has not filed a response. We have r e vi e w e d counsel’s brief and the rele v a n t portions of the record reflected therein. We
concur with counsel’s assessment that the appeal presents no nonfrivolous issue for appellate review. Accordingly, counsel’s m o t i o n f o r leave to withdraw is GRANTED, counsel is excused from furt h e r r e s ponsibilities herein, and the APPEAL IS DISMISSED. See5 T H C I R
. R. 42.2.

2 Case: 10-20847 Document: 00511890978 Page: 2 Date Filed: 06/19/2012
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Commerce

###### Foreign-Trade Zones Board

          - [B-20-2024]

On May 10, 2024, BMW Manufacturing Company, LLC submitted a notification of proposed production activity to the FTZ Board for its facility within Subzone 38A, in Spartanburg, South Carolina.

                    The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the                     **Federal Register**                     inviting public comment (89 FR 42423-42424, May 15, 2024). On September 9, 2024, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including section 400.14.                

Dated: September 9, 2024.

Elizabeth Whiteman,

Executive Secretary.

[FR Doc. 2024-20670 Filed 9-11-24; 8:45 am]

BILLING CODE 3510-DS-P
[Federal Register Volume 89, Number 176 (Wednesday, September 11, 2024)]
[Notices]
[Pages 73682-73683]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-20456]


-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA-4663-DR; Docket ID FEMA-2024-0001]


Kentucky; Amendment No. 15 to Notice of a Major Disaster 
Declaration

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice amends the notice of a major disaster declaration 
for the Commonwealth of Kentucky (FEMA-4663-DR), dated July 22, 2022, 
and related determinations.

DATES: This change occurred on August 16, 2024.

FOR FURTHER INFORMATION CONTACT: Dean Webster, Office of Response and 
Recovery, Federal Emergency Management Agency, 500 C Street SW, 
Washington, DC 20472, (202) 646-2833.

SUPPLEMENTARY INFORMATION: The Federal Emergency Management Agency 
(FEMA) hereby gives notice that pursuant to the authority vested in the 
Administrator, under Executive Order 12148, as amended, Mary Hernandez-
Marrero, of FEMA is appointed to act as the Federal Coordinating 
Officer for this disaster.
    This action terminates the appointment of E. Craig Levy Sr. as 
Federal Coordinating Officer for this disaster.

    The following Catalog of Federal Domestic Assistance Numbers 
(CFDA) are to be used for reporting and drawing funds: 97.030, 
Community Disaster Loans; 97.031, Cora Brown Fund; 97.032, Crisis 
Counseling; 97.033, Disaster Legal Services; 97.034, Disaster 
Unemployment Assistance (DUA); 97.046, Fire Management Assistance 
Grant; 97.048, Disaster Housing Assistance to Individuals and 
Households In Presidentially Declared Disaster Areas; 97.049, 
Presidentially Declared Disaster Assistance--Disaster Housing 
Operations for Individuals and Households; 97.050, Presidentially 
Declared Disaster Assistance to Individuals and Households--Other 
Needs; 97.036, Disaster Grants--Public Assistance

[[Page 73683]]

(Presidentially Declared Disasters); 97.039, Hazard Mitigation 
Grant.

Deanne Criswell,
Administrator, Federal Emergency Management Agency.
[FR Doc. 2024-20456 Filed 9-10-24; 8:45 am]
BILLING CODE 9111-23-P
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   6-MOS
<FISCAL-YEAR-END>                          MAR-31-1996             MAR-31-1996
<PERIOD-START>                             JUL-01-1996             APR-01-1996
<PERIOD-END>                               SEP-30-1996             SEP-30-1996
<CASH>                                           7,190                   7,190
<SECURITIES>                                         0                       0
<RECEIVABLES>                                   14,892                  14,892
<ALLOWANCES>                                         0                       0
<INVENTORY>                                      8,874                   8,874
<CURRENT-ASSETS>                                32,075                  32,075
<PP&E>                                           4,432                   4,432
<DEPRECIATION>                                       0                       0
<TOTAL-ASSETS>                                  41,667                  41,667
<CURRENT-LIABILITIES>                           10,444                  10,444
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                             1                       1
<OTHER-SE>                                      29,519                  29,519
<TOTAL-LIABILITY-AND-EQUITY>                    41,667                  41,667
<SALES>                                         13,453                  25,573
<TOTAL-REVENUES>                                13,453                  25,573
<CGS>                                            7,564                  13,759
<TOTAL-COSTS>                                    7,564                  13,759
<OTHER-EXPENSES>                                 5,424                  10,906
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                   0                       0
<INCOME-PRETAX>                                    469                     705
<INCOME-TAX>                                       164                     249
<INCOME-CONTINUING>                                  0                       0
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                       305                     456
<EPS-PRIMARY>                                      .03                     .05
<EPS-DILUTED>                                        0                       0
        

</TABLE>
**Exhibit 24.02**

**AMBAC FINANCIAL GROUP, INC.**

**Power of Attorney**

KNOW ALL MEN BY THESE PRESENTS that the undersigned director of Ambac Financial Group, Inc., a Delaware corporation, hereby constitutes and appoints eachof **Sean T. Leonard**and**Anne Gill Kelly,** as her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, to sign the **Annual Report on Form 10-Kfor the year ended December 31, 2008**, to be filed with the Securities and Exchange Commission and the New York Stock Exchange, and any and all amendments thereto, and any and all instruments and documents filed as a part of or in connectionwith the said **Form 10-K** or amendments thereto, and does hereby grant unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about thepremises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent shall do or cause to be done by virtue hereof. 

IN WITNESS WHEREOF, the undersigned has subscribed these presents as of this 25th day of February 2009. 

/s/    Jill M. Considine                

Jill M. Considine